公开(公告)号：EP2585171B1

公开(公告)日：2018-12-26

申请号：EP11772857.6

申请日：2011-05-06

Applicant: University Of Central Florida Research Foundation, Inc.

Inventor： HICKMAN, James ,  GUO, Xiufang

IPC: A61P21/00 ,  C12N5/079 ,  C12N5/077

CPC classification number: G01N33/5058 ,  C12N5/0697 ,  C12N2500/90 ,  C12N2501/01 ,  C12N2501/105 ,  C12N2501/13 ,  C12N2501/385 ,  C12N2501/41 ,  C12N2501/58 ,  C12N2502/081 ,  C12N2502/1335 ,  C12N2533/20 ,  C12N2535/10 ,  G01N33/48728 ,  G01N33/6872 ,  G01N33/6887 ,  G01N2500/10

Abstract: A method for forming neuromuscular junctions includes forming functional neuromuscular junctions between motoneurons and muscle cells by co-culturing one or more human motoneurons and one or more rat muscle cells in a substantially serum-free medium. A synthetic mammalian neuromuscular junction includes a human motoneuron functionally linked to a rat muscle cell in a substantially serum-free medium. An artificial substrate may be used to support the one or more neuromuscular junctions.

公开(公告)号：EP3403658A1

公开(公告)日：2018-11-21

申请号：EP18176352.5

申请日：2015-06-26

Applicant: S-BIOMEDICS

Inventor： KIM, Dong Wook ,  KIM, Han Soo

IPC: A61K35/12 ,  A61K39/395 ,  A61P9/10 ,  A61P9/00

CPC classification number: A61K35/30 ,  A61K35/12 ,  A61K39/395 ,  C12N5/0623 ,  C12N2500/25 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2506/02

Abstract: The present invention provides a composition for treating ischemic diseases or neuroinflammatory diseases. PSA-NCAM-positive neural progenitor cells used in the present invention promote angiogenesis in injected tissue and inhibit an inflammatory response. The PSA-NCAM-positive neural progenitor cells can be simply isolated by using an anti-PSA-NCAM-antibody, and exhibit excellent angiogenic and anti-inflammatory activities compared with mesenchymal stem cells, and thus can be useful as a composition for effectively treating ischemic diseases caused by a vascular injury and nerve damage diseases caused by inflammation. In addition, a secretome of the neural progenitor cells of the present invention reduces the ischemic injury site and allows a neurological function to recover, and thus can be used as an agent for treating ischemic diseases and degenerative nervous system disorders such as nerve damage diseases caused by inflammation.

公开(公告)号：EP3196296B1

公开(公告)日：2018-11-21

申请号：EP17159696.8

申请日：2005-09-08

Applicant: Wisconsin Alumni Research Foundation

Inventor： THOMSON, James, A ,  LUDWIG, Tenneille

IPC: C12N5/0735

CPC classification number: C12N5/0606 ,  C12N2500/12 ,  C12N2500/20 ,  C12N2500/25 ,  C12N2500/32 ,  C12N2500/33 ,  C12N2500/36 ,  C12N2500/38 ,  C12N2500/40 ,  C12N2500/44 ,  C12N2500/46 ,  C12N2500/90 ,  C12N2500/98 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/415 ,  C12N2501/845 ,  C12N2501/999 ,  C12N2533/52 ,  C12N2533/54

Abstract: Previous methods for culturing human embryonic stem cells have required either fibroblast feeder cells or a medium, which has been exposed to fibroblast feeder cells in order to maintain the stem cells in an undifferentiated state. It has now been found that if high levels of fibroblast growth factor are used in a medium with gamma amino butyric acid, pipecholic acid, lithium and lipids, the stem cells will remain undifferentiated indefinitely through multiple passages, even without feeder cells or conditioned medium. A humanized matrix of human proteins can be used as a basement matrix to culture the cells. New lines of human embryonic stem cells made using these culture conditions, the medium and the matrix, will never have been exposed to animal cells, animal products, feeder cells or conditioned medium.

公开(公告)号：EP3024928B1

公开(公告)日：2018-11-21

申请号：EP14744018.4

申请日：2014-07-18

Applicant: F. Hoffmann-La Roche AG

Inventor： GRAF, Martin ,  IACONE, Roberto ,  THOMA, Eva, Christina

IPC: A61K35/30 ,  C12N5/0797

CPC classification number: C12N5/0623 ,  A61K35/30 ,  C12N2500/90 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/1307

Abstract: This application relates to a method for differentiating somatic cells into multi-competent neural crest cells based on linked steps of chemically defined medium inductions. Neural crest cells are able to differentiate into numerous cell types like Schwann cells, chondrocytes, smooth muscle cells or adipocytes.

公开(公告)号：EP2611452B1

公开(公告)日：2018-10-24

申请号：EP11758028.2

申请日：2011-09-02

Applicant: Life Technologies Corporation

Inventor： CAMPBELL, Andrew ,  CHASE, Lucas ,  VEMURI, Mohanachari

IPC: C12N5/0775 ,  A61K35/28 ,  C12M1/12

CPC classification number: C12N5/0663 ,  A61K35/12 ,  C12M25/16 ,  C12N2500/90 ,  C12N2500/98 ,  C12N2511/00 ,  C12N2531/00 ,  C12N2533/00

Abstract: The present invention relates to growing stem cells, for e.g., MSCs, in large-scale under GMP-compliance, using media and reagents that satisfy GMP requirements, while maintaining stemness, for effective downstream therapeutic use, which include but are not limited to, stem cell therapy, production of products, such as beneficial factors, recombinant proteins, etc. obtained from such stem cells.

公开(公告)号：EP2556147B1

公开(公告)日：2018-10-03

申请号：EP11718764.1

申请日：2011-04-08

Applicant: The University Court Of The University of Edinburgh

Inventor： NOBLE, Brendon, Stewart ,  PIER, David, Matthew

IPC: C12N5/077 ,  A61K35/32 ,  A61P19/02

CPC classification number: C12N5/0655 ,  A61K35/32 ,  C12N5/0662 ,  C12N2500/25 ,  C12N2500/84 ,  C12N2500/90 ,  C12N2501/15 ,  C12N2501/39 ,  C12N2506/02 ,  C12N2506/03 ,  G01N33/5044

Abstract: The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells.

公开(公告)号：EP3372673A1

公开(公告)日：2018-09-12

申请号：EP18168060.4

申请日：2015-09-08

Applicant: Riken ,  Sumitomo Chemical Company Limited

Inventor： MUGURUMA, Keiko ,  SASAI, Yoshiki

IPC: C12N5/0735 ,  C12N5/079 ,  C12N5/10 ,  C12N15/09 ,  C12N5/0793

CPC classification number: C12N5/0619 ,  C12N5/10 ,  C12N15/09 ,  C12N2500/90 ,  C12N2501/113 ,  C12N2501/19 ,  C12N2501/21 ,  C12N2501/33 ,  C12N2506/03 ,  C12N2506/08

Abstract: The present invention provides a method for producing a human cell aggregate containing a midbrain-hindbrain boundary neural progenitor tissue, including subjecting an aggregate of human pluripotent stem cells to suspension culturing in a serum-free medium containing insulin, and treating, in the suspension culturing, the aggregate of human pluripotent stem cells or a human cell aggregate derived therefrom with a ROCK inhibitor, a TGFβ signal inhibitor, and a first fibroblast growth factor. Furthermore, the human cell aggregate containing the midbrain-hindbrain boundary neural progenitor tissue is subjected to suspension culturing in a serum-free medium to induce formation of a neuroepithelial structure by neural progenitor in the neural progenitor tissue, whereby the human cell aggregate containing the cerebellar plate tissue can be obtained.

公开(公告)号：EP2401363B1

公开(公告)日：2018-08-22

申请号：EP10710685.8

申请日：2010-02-25

Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.

Inventor： DEKEL, Benjamin ,  HARARI-STEINBERG, Orit

IPC: C12N5/074

CPC classification number: A61K35/22 ,  C12N5/0686 ,  C12N5/0687 ,  C12N5/0696 ,  C12N15/85 ,  C12N2500/90 ,  C12N2501/06 ,  C12N2501/065 ,  C12N2501/415 ,  C12N2506/25

Abstract: Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells.

公开(公告)号：EP2496940B1

公开(公告)日：2018-08-15

申请号：EP10779607.0

申请日：2010-11-05

Applicant: Primegen Biotech, LLC dba Reprocyte ,  Chow, Johnny Yung-Chiong

Inventor： IZADYAR, Fariborz ,  MARH, Joel ,  MAKI, Chad ,  PACCHIAROTTI, Jason ,  RAMOS, Thomas ,  HOWERTON, Kyle ,  WONG, Jadelind ,  OLMSTEAD, Marnie ,  CHOW, Johny, Yung-Chiong ,  YUEN, Constance

IPC: G01N33/50 ,  C12N5/075 ,  C12N5/076 ,  A01K67/027

CPC classification number: C12N5/0609 ,  C12N5/061 ,  C12N2500/25 ,  C12N2500/30 ,  C12N2500/84 ,  C12N2500/90 ,  C12N2501/06 ,  C12N2501/10 ,  C12N2501/11 ,  C12N2501/119 ,  C12N2501/125 ,  C12N2501/13 ,  C12N2501/15 ,  C12N2501/235 ,  C12N2501/31 ,  C12N2501/385 ,  C12N2501/998 ,  C12N2509/00 ,  C12N2533/54 ,  C12N2533/90

Abstract: Methods and systems are provided for the isolation, characterization, cryopreservation and banking of human germline stem cells and gonadal tissue. Also disclosed are methods for the transplanting of the cryopreserved cells to repopulate a sterile reproductive organ.

公开(公告)号：EP3354721A1

公开(公告)日：2018-08-01

申请号：EP16844466.9

申请日：2016-09-08

Applicant: Sumitomo Dainippon Pharma Co., Ltd. ,  HEALIOS K.K.

Inventor： ANDO, Satoshi ,  KURODA, Takao

IPC: C12N5/071 ,  A61K35/30 ,  A61K35/545 ,  A61L27/00 ,  A61P27/02 ,  C12Q1/02

CPC classification number: C12N5/0621 ,  A61K35/30 ,  A61K35/545 ,  A61L27/00 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/999 ,  C12N2506/03 ,  C12Q1/02 ,  G01N33/5014 ,  G01N33/5044

Abstract: The present invention provides a method for more efficiently producing retinal pigment epithelial cells from pluripotent stem cells. The method of the present invention for producing retinal pigment epithelial cells includes the following steps:
(1) a first step for culturing a pluripotent stem cell in a medium comprising an FGF receptor inhibitor and/or an MEK inhibitor for a period of not more than 30 days, and
(2) a second step for culturing the cell obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.